$SPRC Cashflow Statement | Understand Stock

$SPRC

$0.83 -$0.02 (2.35%) Close

$SPRC Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to the profit or loss items:
Depreciation and amortization
Impairment of an intangible asset
Cost of share-based payment
Impairment of loan (see note 8c)
Subsidiaries’ cost of share-based payment (see note 25)
Finance income, net
Equity losses
Deemed stock exchange listing expense
Gain on sale of an associate accounted for under the equity method
Losses from remeasurement of investment in financial assets
Total adjustments to the profit or loss
Decrease (increase) in other accounts receivable
Working capital adjustments:
Decrease in trade receivables
Decrease (increase) in other accounts receivable
Increase in inventory
Decrease (increase) in inventory
Increase (decrease) in trade payables
Increase (decrease) in other payables
Increase (decrease) in related parties
Working capital

Net cash used in operating activities
Cash flows from investing activities:
Withdrawal of (investment in) restricted bank deposits
Withdrawal of (investment in) short-term bank deposits
Purchase of property and equipment
Sale of property and equipment
Investment in an associate accounted for under the equity method
Loan to related parties
Investments in financial assets
Purchase of intangible asset
Proceeds from sale of an affiliate accounted for under the equity method (see note 7)

Net cash used in investing activities
Cash flows from financing activities:
Proceeds from issue of share capital (net of issuance expenses)
Proceeds from exercise of warrants
Payment of issuance expenses related to previous period
Sale of non-controlling interest in a subsidiary
Repayment of loans
Receipt of loans
Proceeds from deemed issuance of shares by a subsidiary (see (b) below)
Proceeds from issuance of convertible debentures (see note 18i)
Interest paid on lease liability
Repayment of lease liability
Repayment of short-term credit

Net cash provided by financing activities
Increase (decrease) in cash
Cash at the beginning of the period
Cash at the end of the period
(a) Significant non-cash financing and investing activities:
Right-of-use asset recognized with corresponding lease liability
Registration of warrants
Unpaid issue expenses
Investment in financial asset
Exchange of MitoCareX shares with Nexentis Inc. shares (see Note 7)
Sale of minority interest in subsidiary
Purchase of financial assets at fair value through profit or loss
Conversion of convertible debentures

Comments